|
- Zongertinib in Previously Treated HER2-Mutant Non–Small-Cell Lung . . .
We evaluated zongertinib in a multicohort, phase 1a–1b trial involving patients with advanced or metastatic HER2 -mutant NSCLC
- Zongertinib - Wikipedia
Zongertinib, sold under the brand name Hernexeos, is an anti-cancer medication used for the treatment of non-small cell lung cancer [1][2] Zongertinib is a kinase inhibitor of human epidermal growth factor receptor 2 (HER2) [1][3][4] It is taken by mouth
- Zongertinib (oral route) - Side effects dosage - Mayo Clinic
Zongertinib belongs to the group of medicines called antineoplastics (cancer medicines) It works by interfering with the growth of cancer cells, which are eventually destroyed
- Treatment for HER2 Metastatic NSCLC | HERNEXEOS® (zongertinib tablets)
What is HERNEXEOS (zongertinib tablets)? HERNEXEOS is a prescription medicine used to treat adults with a type of lung cancer called non-squamous non-small cell lung cancer (NSCLC) that: who have previously received treatment by mouth or injection (systemic therapy)
- FDA grants accelerated approval to zongertinib for non-squamous NSCLC
On August 8, 2025, the Food and Drug Administration granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc ), a kinase inhibitor, for adults with
- Zongertinib: MedlinePlus Drug Information
Zongertinib is in a class of medications called kinase inhibitors It works by blocking the action of an abnormal protein that signals cancer cells to multiply
- Zongertinib Uses, Side Effects Warnings - Drugs. com
What is zongertinib? Zongertinib is used in adults to treat non-squamous non-small cell lung cancer Zongertinib is used when the cancer has spread to other parts of the body, cannot be removed by surgery, or when other cancer treatments did not work or have stopped working
- Targeting HER2 in cancer: The story of zongertinib
Zongertinib, our investigational HER2 tyrosine kinase inhibitor, is being developed as a potential oral treatment for people with NSCLC with a specific mutation in the HER2 gene
|
|
|